In a groundbreaking collaboration, iTeos Therapeutics, Inc. (Nasdaq: ITOS) and GSK have embarked on an ambitious endeavor to tackle one of the most formidable challenges in oncology: non-small cell lung cancer (NSCLC). On June 17, 2024, the two companies announced the initiation of the GALAXIES Lung-301 Phase 3 study, an extensive, globally scoped investigation assessing the efficacy of a novel therapeutic regimen involving belrestotug and dostarlimab. This doublet combination is set against the prevailing standard treatment of placebo and pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer.
Background and Rationale’
Non-small cell lung cancer (NSCLC) represents the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. Therapies targeting programmed death-ligand 1 (PD-L1) have shown significant promise, particularly in tumors showcasing high PD-L1 expression. Despite advancements, the prognosis for advanced NSCLC remains dismal, necessitating the exploration of more effective therapeutic agents and combinations.
Belrestotug, an innovative compound developed by iTeos Therapeutics, is part of a new generation of immuno-oncology therapies aimed at enhancing the body’s ability to combat cancer. Dostarlimab, marketed by GSK, is an anti-PD-1 monoclonal antibody that has demonstrated substantial efficacy in various cancer types, including NSCLC.
Study Design and s’
The GALAXIES Lung-301 study is a global Phase 3 registration trial designed to evaluate the efficacy, safety, and tolerability of belrestotug in combination with dostarlimab. The trial’s primary comparison is between the novel doublet therapy and the standard treatment regimen of placebo plus pembrolizumaban established anti-PD-1 therapy.
The study targets patients with previously untreated, unresectable, locally advanced or metastatic NSCLC characterized by PD-L1 expression. The choice of this patient population is crucial as PD-L1 positivity is a biomarker that indicates a higher likelihood of response to immunotherapy.
Key s of the study include:
- ’Primary Endpoint’: Progression-free survival (PFS), which measures the time from the commencement of the study until disease progression or death.
- ’Secondary Endpoints’: Overall survival (OS), response rate (ORR), duration of response (DoR), and quality of life (QoL) assessments.
Mechanism of Action’
Belrestotug and dostarlimab are designed to work synergistically to augment anti-tumor immunity. Belrestotug, a first-in-class agent, is hypothesized to modulate the tumor microenvironment, making it more conducive to an immune response. Dostarlimab, on the other hand, inhibits the PD-1 pathway, a mechanism cancer cells exploit to evade immune detection. By combining these two agents, the study aims to demonstrate superior anti-tumor activity compared to the current standard-of-care.
Potential Impact’
The initiation of the GALAXIES Lung-301 study marks a pivotal moment in the quest to improve outcomes for patients with advanced NSCLC. If successful, the belrestotug and dostarlimab combination could redefine the therapeutic landscape for this patient population, offering a new beacon of hope where limited options currently exist.
Moreover, this study highlights the importance of collaboration in the biopharmaceutical industry. The partnership between iTeos Therapeutics and GSK brings together complementary expertise and resources, significantly enhancing the potential for groundbreaking discoveries.
Conclusion’
As the GALAXIES Lung-301 study progresses, the oncology community will be watching closely, hopeful for the validation of a novel therapeutic approach that could potentially transform the standard of care for non-small cell lung cancer. The combined efforts of iTeos Therapeutics and GSK underscore a shared commitment to advancing cancer treatment and improving patient outcomes. With the potential to set a new benchmark in NSCLC therapy, the results of this study could have far-reaching implications for the future of oncology and personalized medicine.
Comments